What types of peptides does Thinheal supply?

Thinheal supplies generic peptide APIs, therapeutic peptides, GLP-1 analogues such as Semaglutide (CAS 910463-68-2), GLP-2 analogues, other gastrointestinal peptides, other therapeutic peptide APIs and cosmetic peptides for skin-care formulations.

Does Thinheal offer custom peptide development and CDMO services?

Yes. Thinheal provides project-based contract research and development, contract manufacturing and sales support, covering custom peptide development, process optimization, scale-up and commercial API supply through to formulation development.

What is Thinheal's production capacity?

Thinheal operates an R&D center and a production base in Hangzhou, China. Total production capacity for chemically synthesized peptides has reached the multi-ton level.

What documentation can buyers expect?

Each shipment is accompanied by batch analytical data such as a Certificate of Analysis. Additional documents required for supplier qualification or regulatory filings can be scoped with the sales and technical team for each project.

How do international buyers contact the right sales team?

Thinheal runs regional sales desks for USA & Europe, Russia & CIS & Europe, Asia, and the Middle East & East Asia. Buyers can also email info@thinheal.com or call +86 0571-86758863.

High-Quality Mazdutide CAS NO: 2259884-03-0 Manufacturers, Pricelist

1 / 1

High-Quality Mazdutide CAS NO: 2259884-03-0 Manufacturers, Pricelist

Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for weight loss, offering a unique mechanism that enhances weight-loss efficacy while reducing visceral fat and delivering comprehensive metabolic benefits, named by Fierce Pharma as one of the top ten most anticipated drugs globally in 2025.

Send Inquiry

Product Description

Therapeutic Areas

With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs

With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap the rewards in the near term.

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s dual GLP-1/glucagon (GCP) receptor agonist mazdutide for chronic weight management in Chinese adults who are overweight or have obesity.

Approval Requirement: Patients must also have at least one weight-related comorbidity, such as high blood sugar or blood pressure, according to a statement from the country’s drug regulator.

Outlook & Development

The green light earns mazdutide the distinction of being the world’s first dual GCG/GLP-1 med, Innovent said in a June 27 press release. Innovent paid an undisclosed sum to secure the Chinese rights to mazdutide from Lilly in 2019, while Lilly continues to hold the rights to the metabolic drug outside of China, where it has yet to win approval.

Mazdutide, as a new entrant in the booming GLP-1 scene for obesity, recently ranked among Fierce Pharma’s top 10 most anticipated drug launches of 2025. That report leveraged data on prospective launches from intelligence and analytics firm Evaluate, which has estimated that the drug could reach $1.3 billion in 2030 sales.

By targeting the GCG receptor, Lilly and Innovent figure mazdutide should help increase the body’s energy expenditure, spurring changes in the liver, brain and white and brown adipose tissue that complement the reduced energy intake triggered by GLP-1 activation.

China’s drug regulator based its approval on data from Innovent’s phase 3 GLORY-1 study in more than 600 adults in China who are overweight or obese.

12%

Weight Loss (4 mg Dose)

14.8%

Weight Loss (6 mg Dose)

0.5%

Weight Loss (Placebo)

Frequently Asked Questions

What is Mazdutide and how does it work?

Mazdutide is the world's first approved dual GCG/GLP-1 receptor agonist for weight loss. It targets both the GCG and GLP-1 receptors to increase the body's energy expenditure—spurring metabolic changes in the liver, brain, and adipose tissue—while simultaneously reducing energy intake.

Who approved Mazdutide and for which patients?

China’s National Medical Products Administration (NMPA) approved Mazdutide for chronic weight management in adults who are overweight or obese and have at least one weight-related comorbidity, such as high blood sugar or high blood pressure.

Who holds the commercial rights to Mazdutide?

Innovent Biologics secured the Chinese rights to Mazdutide from Eli Lilly in 2019. Eli Lilly continues to hold the rights to the drug outside of China, where it has yet to win approval.

What were the results of the Phase 3 GLORY-1 clinical trial?

In the 48-week trial involving over 600 adults, patients on Mazdutide 4 mg achieved an average weight loss of 12%, patients on 6 mg achieved 14.8%, compared to a 0.5% weight loss in the placebo group relative to baseline.

What is the market outlook and projected sales for Mazdutide?

Named by Fierce Pharma as one of the top 10 most anticipated drug launches of 2025, intelligence and analytics firm Evaluate estimates that Mazdutide could reach $1.3 billion in sales by 2030.